Amicus Briefs
Boehringer Ingelheim Pharmaceuticals, Inc. v. HHS
CASE SUMMARY
NCLA urges the Second Circuit to rule it is unlawful for HHS to hold a company’s business hostage until it surrenders its constitutional property rights. The law at issue violates the “unconstitutional conditions” doctrine, which prevents the indirect trampling of constitutional rights.
Two years ago, Congress enacted the Inflation Reduction Act of 2022, part of which sought to lower Medicare drug costs. Instead of achieving this important goal lawfully, it chose an approach that cannot be reconciled with the Constitution. The Medicare cost reduction program’s goal is to force pharmaceutical companies to sell their products at less than market value. It cannot do so directly without violating the Takings Clause of the Fifth Amendment. So, it tells companies: Either forfeit your constitutional right or pay excise taxes and penalties on your products that are so draconian they will destroy your business. The U.S. Supreme Court has already spoken to this kind of behavior, choosing the descriptive word “extortion.”
It may be politically popular, albeit short-sighted, to curtail the constitutional rights of big companies, but if Congress can do this to the pharmaceutical companies, then it can do it to mom-and-pop businesses, too. Americans deserve better than a Congress that engages in extortionate behavior, and they have a right to be free of even sophisticated attempts to undermine the Constitution.